Business
MediciNova Receives a New Patent Covering MN-001 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia in Korea
LA JOLLA, Calif., Feb. 01, 2022 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the
About this update from Medicinova, Inc.
[{"type":"text","content":"LA JOLLA, Calif., Feb. 01, 2022 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a new patent from the Korean Intellectual Property Office which covers MN-001 (tipelukast) for the treatment of hypertriglyceridemia, hypercholesterolemia, and hyperlipoproteinemia. Once issued, the patent maturing from this allowed patent application is expected to expire no earlier than July 2034. The allowed claims cover a pharmaceutical composition comprising MN-001 (tipelukast) for reducing a triglyceride blood level, reducing a total cholesterol blood level, and reducing a low-density lipoprotein (LDL) blood level. The allowed claims cover oral administration including liquid and solid dosage forms. The allowed claims cover a wide range of doses of MN-001 (tipelukast) and a range of different dosing frequencies. Kazuko Matsuda, M.D. Ph.D, MPH., Chief Medical Officer, MediciNova, Inc., commented, “We are very pleased to receive notice that this new patent will be granted. As we already have granted patents for similar indications in the U.S., Europe, Japan, and China, we believe this additional patent in Korea could increase the potential value of MN-001. In our Phase 2 trial which enrolled subjects with NASH or NAFLD with hypertriglyceridemia, MN-001 demonstrated a statistically significant reduction in mean serum triglycerides after 8 weeks of treatment.” About MN-001 MN-001 (tipelukast) is a novel, orally bioavailable, small molecule compound thought to exert its effects through several mechanisms to produce its anti-inflammatory and anti-fibrotic activity in preclinical models, including leukotriene (LT) receptor antagonism, inhibition of phosphodiesterases (PDE) (mainly 3 and 4), and inhibition of 5-lipoxygenase (5-LO). The 5-LO/LT pathway has been postulated as a pathogenic factor in fibrosis development, and MN-001's inhibitory effect on 5-LO and the 5-LO/LT pathway is considered to be a novel approach to treat fibrosis. MN-001 has been shown to down-regulate expression of genes that promote fibrosis including LOXL2, Collagen Type 1 and TIMP-1. MN-001 has also been shown to down-regulate expression of genes that promote inflammation including CCR2 and MCP-1. In addit...